International Business Machines Corp. (IBM - $256.11)News Reports CEO Sees More AI Deals in Friendlier Regulatory Climate.According to Bloomberg, IBM's CEO Arvind Krishna signaled on March 17, 2026, that the company intends to continue pursuing M&A in AI and hybrid cloud, citing a materially mo
A director at International Paper Co bought 26,092 shares at 38.327USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 202...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing ...
Two Directors at International Business Machines Corp bought/maiden bought 484 shares at between 233.326USD and 237.829USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Data Environments Not Getting Replaced; IBM Focused on Building Moat. IBM has been focused intently on building out its data moat through organic and inorganic verticals as the company continues to develop a moat around its data with more enterprises looking to gain more from their data. The compan
Valuation Compression is Disconnected from Forward Earnings Risk. The magnitude of multiple contractions implies structural revenue impairment. Yet there is no evidence of customer churn acceleration, budget freezes, or competitive displacement in reported results The market is reacting to demo ris
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be availa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.